Protein profiles distinguish stable and progressive chronic lymphocytic leukemia

Pauline Y. Huang, Swetlana Mactier, Natalie Armacki, O. Giles Best, Larissa Belov, Kimberley L. Kaufman, Dana Pascovici, Stephen P. Mulligan, Richard I. Christopherson

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


Patients with a stable chronic lymphocytic leukemia (CLL) double their blood lymphocyte count in >5 years, but may develop progressive disease with lymphocytes doubling in <12 months. To identify a protein signature for progressive CLL, whole cell extracts of peripheral blood mononuclear cells from patients with CLL (n = 27) were screened using iTRAQ (isobaric tags for relative and absolute quantification) analysis. A total of 84 differentially abundant proteins were identified from patients with stable and progressive CLL. Subsequently, 32 of these proteins were quantified by SRM (selected reaction monitoring) using extracts of purified CD19 CLL cells from patients (n = 50). Hierarchical clustering of these protein profiles showed two clusters of patients that correlated with progressive and stable CLL, providing signatures that should be useful for triaging patients. Some of the proteins in the progressive cluster have not been linked with CLL, for example, glutamate dehydrogenase 1 and transcription intermediary factor 1-beta.
Original languageEnglish
Pages (from-to)1033-1043
Number of pages11
JournalLeukemia and Lymphoma
Issue number5
Publication statusPublished - May 2016

Bibliographical note

Corrigenda: Huang PY, mactier S, armacki N, et al. Protein profiles distinguish stable and progressive chronic lymphocytic leukemia.
Leukemia & Lymphoma, 2016; Vol. 57, pp. 1033–1043.


  • Chronic lymphocytic leukemia
  • iTRAQ
  • mass spectrometry
  • prognostic markers
  • proteomics
  • selected reaction monitoring


Dive into the research topics of 'Protein profiles distinguish stable and progressive chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this